1. Home
  2. THCH vs ENTX Comparison

THCH vs ENTX Comparison

Compare THCH & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TH International Limited Ordinary shares

THCH

TH International Limited Ordinary shares

N/A

Current Price

$2.09

Market Cap

58.9M

Sector

Finance

ML Signal

N/A

ENTX

Entera Bio Ltd.

HOLD

Current Price

$1.31

Market Cap

62.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
THCH
ENTX
Founded
2018
2010
Country
China
Israel
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.9M
62.6M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
THCH
ENTX
Price
$2.09
$1.31
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$9.00
AVG Volume (30 Days)
5.9K
124.9K
Earning Date
04-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.25
Revenue
N/A
$42,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$5.44
Revenue Growth
N/A
N/A
52 Week Low
$1.69
$0.91
52 Week High
$3.25
$3.22

Technical Indicators

Market Signals
Indicator
THCH
ENTX
Relative Strength Index (RSI) 43.50 55.67
Support Level $1.70 $1.12
Resistance Level $2.31 $1.38
Average True Range (ATR) 0.19 0.10
MACD -0.02 0.02
Stochastic Oscillator 33.87 76.67

Price Performance

Historical Comparison
THCH
ENTX

About THCH TH International Limited Ordinary shares

TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under single reportable segment, Tim Hortons. The company's revenue is derived from its operations in the PRC.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Share on Social Networks: